Table 3.
Cox-proportional hazard regression for the cerebrovascular disease (CVD) and myocardial infarction (MI) by the proportion of days covered (PDC) with the stratification by sex.
| Proportion of days covered (PDC) | P for trend | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ≥0.80 | 0.60–0.79 | 0.40–0.59 | 0.20–0.39 | <0.20 | ||||||
| Hazard ratio | 95% CI | Hazard ratio | 95% CI | Hazard ratio | 95% CI | Hazard ratio | 95% CI | |||
| Total No. of participants | N = 22,261 | N = 11,459 | N = 10,279 | N = 10,393 | N = 10,675 | |||||
| Cerebrovascular disease | ||||||||||
| Total person-years | 204,354.8 | 104,059.3 | 92,813.8 | 92,862.4 | 94,075.1 | |||||
| All [No. of event] | N = 1,584 | N = 906 | N = 829 | N = 948 | N = 1,019 | |||||
| Model 1 | Reference | 1.21 | 1.11–1.31 | 1.21 | 1.12–1.32 | 1.38 | 1.27–1.50 | 1.44 | 1.33–1.56 | <0.001 |
| Model 2 | 1.19 | 1.10–1.29 | 1.18 | 1.09–1.29 | 1.35 | 1.24–1.46 | 1.41 | 1.30–1.52 | <0.001 | |
| Men [No. of event] | N = 931 | N = 558 | N = 501 | N = 577 | N = 594 | |||||
| Model 1 | Reference | 1.26 | 1.14–1.40 | 1.23 | 1.10–1.37 | 1.43 | 1.29–1.59 | 1.43 | 1.29–1.59 | <0.001 |
| Model 2 | 1.24 | 1.12–1.38 | 1.19 | 1.07–1.33 | 1.39 | 1.25–1.54 | 1.39 | 1.26–1.55 | <0.001 | |
| Women [No. of event] | N = 653 | N = 348 | N = 328 | N = 371 | N = 425 | |||||
| Model 1 | Reference | 1.12 | 0.99–1.28 | 1.18 | 1.04–1.35 | 1.31 | 1.15–1.48 | 1.44 | 1.27–1.63 | <0.001 |
| Model 2 | 1.12 | 0.98–1.27 | 1.16 | 1.01–1.32 | 1.27 | 1.12–1.45 | 1.41 | 1.25–1.59 | <0.001 | |
| Myocardial infarction | ||||||||||
| Total person-years | 209,197.3 | 106,730.9 | 95,272.1 | 95,506.6 | 97,376.5 | |||||
| All [No. of event] | N = 426 | N = 229 | N = 199 | N = 237 | N = 203 | |||||
| Model 1 | Reference | 1.10 | 0.94–1.29 | 1.05 | 0.89–1.24 | 1.25 | 1.06–1.46 | 1.04 | 0.88–1.23 | 0.094 |
| Model 2 | 1.09 | 0.93–1.28 | 1.03 | 0.87–1.22 | 1.23 | 1.05–1.44 | 1.02 | 0.86–1.21 | 0.138 | |
| Men [No. of event] | N = 326 | N = 168 | N = 150 | N = 172 | N = 150 | |||||
| Model 1 | Reference | 1.03 | 0.86–1.24 | 1.01 | 0.83–1.22 | 1.16 | 0.96–1.39 | 0.98 | 0.81–1.20 | 0.566 |
| Model 2 | 1.02 | 0.85–1.23 | 0.99 | 0.81–1.20 | 1.14 | 0.95–1.37 | 0.97 | 0.80–1.18 | 0.595 | |
| Women [No. of event] | N = 100 | N = 61 | N = 49 | N = 65 | N = 53 | |||||
| Model 1 | Reference | 1.29 | 0.94–1.77 | 1.15 | 0.81–1.61 | 1.48 | 1.08–2.02 | 1.14 | 0.81–1.59 | 0.159 |
| Model 2 | 1.28 | 0.93–1.76 | 1.11 | 0.79–1.57 | 1.42 | 1.03–1.94 | 1.10 | 0.79–1.54 | 0.236 | |
Model 1: adjusted for age and sex (only age in stratified analysis). Model 2: adjusted for age, sex, disability, CCI, monthly contribution, insurance type, medical institution type, hypertension, and active ingredients of oral hypoglycemic agents (except sex in stratified analysis).